太龙药业控股股东拟变更为江药控股 股票明日开市复牌

Core Viewpoint - The announcement indicates a significant change in the control of Tailong Pharmaceutical, with Zhengzhou Tai Rong Industrial Investment Co., Ltd. planning to transfer shares to Jiangyao Holdings, leading to a shift in the company's controlling shareholder and actual controller [1][2][4] Group 1: Share Transfer and Control Change - Zhengzhou Tai Rong Industrial Investment Co., Ltd. will transfer 8.73% of Tailong Pharmaceutical's shares to Jiangyao Holdings at a price of 11.043 CNY per share, totaling 553 million CNY [1] - Following the share transfer, Jiangyao Holdings will hold 7.37% of the shares and, through a concerted action arrangement, will control a total of 14.37% of the company [2] - The controlling shareholder will change from Zhengzhou Tai Rong to Jiangyao Holdings, with the actual controller shifting from Zhengzhou High-tech Industrial Development Zone Management Committee to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [2] Group 2: Capital Increase and Fund Utilization - Jiangyao Holdings plans to subscribe for up to 74.6052 million shares of Tailong Pharmaceutical, with the total fundraising not exceeding 454 million CNY, aimed at enhancing working capital and repaying interest-bearing debts [3] - Upon completion of the share transfer and capital increase, Jiangyao Holdings is expected to hold 125 million shares, representing 19.23% of the total share capital post-issuance [3] Group 3: Strategic Implications - The partnership with Jiangyao Holdings is expected to leverage its resources in commercial circulation, retail terminals, and e-commerce to enhance market penetration and sales growth for Tailong Pharmaceutical's existing products [4] - The collaboration aims to integrate resources and competitive advantages in the biopharmaceutical sector, promoting high-quality development and enhancing the company's profitability and competitiveness [4] - The fundraising will provide sufficient operational capital support for Tailong Pharmaceutical's strategic optimization and business layout, helping the company seize industry development opportunities and improve shareholder returns [4]